Skip to main content
Ondine Biomedical Inc. logo

Ondine Biomedical Inc. — Investor Relations & Filings

Ticker · OBI ISIN · CA68234M2058 LEI · 9845005B69E07CGF4A56 TSXV Manufacturing
Open in API
Filings indexed 221 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country CA Canada
Listing TSXV OBI

About Ondine Biomedical Inc.

https://ondinebio.com/

Ondine Biomedical Inc. is a life sciences company that develops and commercializes photodisinfection-based therapies to prevent and treat a broad spectrum of infections, including those caused by drug-resistant pathogens. The company's patented platform technology involves applying a photosensitive agent to a targeted area, followed by illumination with non-thermal laser light. This process creates an oxidative burst that rapidly destroys pathogens like bacteria, viruses, and fungi without inducing microbial resistance. Its lead product, Steriwave™, is a nasal decolonization therapy used to eradicate pathogens in the nasal cavity, primarily to reduce the risk of healthcare-associated infections (HAIs) such as post-operative surgical site infections. The company's product pipeline is exploring applications for chronic rhinosinusitis, burns, wounds, and ventilator-associated pneumonia.

Recent filings

Filing Released Lang Actions
Notification of major holdings - hInsight-NX, LLC
Regulatory Filings
2026-05-06 English
Notification of major holdings - Carolyn Cross
Regulatory Filings
2026-05-06 English
Notification of major holdings - Pentwater
Regulatory Filings
2026-05-05 English
Ondine Presented Steriwave Data at IPC 2026
Regulatory Filings Classification · 95% confidence The document is a press release announcing Ondine Biomedical's presentation of Steriwave data at a recent Infection Prevention and Control Conference. It discusses the content of the presentation, clinical and economic impacts, and company information. There are no financial statements, regulatory filings, or detailed financial results. The document is an announcement of a corporate event and product information rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general corporate announcement related to product and conference participation, which aligns best with the Regulatory Filings (RNS) category as a general announcement that does not fit other specific categories.
2026-04-30 English
Result of Fundraise & TVR
Capital/Financing Update Classification · 95% confidence The document is an RNS announcement detailing the successful completion of a £5 million fundraising (placing and subscription), the issuance of 41.7 million new shares, related party director subscriptions, use of proceeds, and total voting rights. This is a clear update on the company’s capital‐raising activity and changes to its capital structure. Therefore, it belongs in the Capital/Financing Update category.
2026-04-29 English
Proposed c.£5 million (C$9.23 million) Fundraise
Capital/Financing Update Classification · 87% confidence The document is an RNS announcement by Ondine Biomedical Inc. detailing a proposed £5 million fundraising via a placing and subscription of new common shares, including issue price, admitting conditions, participation by directors, use of proceeds, and timetable. This constitutes a corporate financing update regarding capital raising activities. It is not a full financial report, dividend notice, or AGM material, nor a regulatory filing announcing publication of a report. Therefore, it is classified as a Capital/Financing Update.
2026-04-28 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.